Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Carcinoma, Hepatocellular × camrelizumab × Clear all

Phase

Phase 2 16 Phase NA 6 Phase 3 3 Phase 2/3 3 Phase 1/2 3 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Oligometastatic Gastrointestinal Cancer 1 Nasopharyngeal Carcinoma 1 Mouth Neoplasms 1 Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi) 1 Hematologic Neoplasms 1 Head and Neck Neoplasms 1 Gastrointestinal Neoplasms 1 Extensive Stage Small Cell Lung Cancer 1 Esophageal Squamous Cell Carcinoma 1 Carcinoma, Hepatocellular 1 BRAF V600E-mutated /MSS Metastatic Colorectal Cancer 1 Advanced Tumors 1 Advanced Solid Tumors 1 Advanced Solid Tumor 1 Advanced Gastric Cancer 1 Advanced Cervical Cancer 1

Interventions

Sorafenib 33 Nivolumab 18 pembrolizumab 14 Bevacizumab 11 Cyclophosphamide 10 durvalumab 9 fludarabine 8 atezolizumab 7 Magnetic Resonance Spectroscopy 7 Ipilimumab 7 lenvatinib 6 Radiotherapy 6 Irinotecan 6 Radiosurgery 5 Oxaliplatin 5 Leucovorin 5 tremelimumab 4 tislelizumab 4 sintilimab 4 budigalimab 4 Specimen Handling 4 Interleukin-2 4 Fluorouracil 4 Doxorubicin 4 Capecitabine 4 toripalimab 3 cabozantinib 3 Sirolimus 3 Melphalan 3 Injections 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05031949 2023-12-19

CCGLC-003

Tongji Hospital

Phase 1 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡